- Details
- Leslie Ballas interviews Hoda Abdel-Aty about the STAMPEDE2 SABR trial, a Phase III randomized study investigating stereotactic ablative body radiotherapy in newly diagnosed oligometastatic prostate cancer patients starting androgen deprivation therapy. Dr. Abdel-Aty discusses the trial design, which compares standard-of-care treatment with or without SABR to metastases. The study defines oligomet...
|
- Details
- Neeraj Agarwal interviews Arun Azad about the UpFrontPSMA study. Dr. Azad discusses the randomized Phase II trial comparing sequential lutetium-PSMA-617 and docetaxel versus docetaxel alone in metastatic hormone-sensitive prostate cancer (mHSPC). The study demonstrates significant improvements in the primary endpoint of undetectable PSA at 48 weeks and several secondary endpoints with the addition...
|
- Details
- Neeraj Agarwal interviews Marta Garcia de Herreros about presentation on tumor suppressor gene (TSG) signatures in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garcia de Herreros discusses the TSG-low signature, based on low expression of RB1, PTEN, and TP53 genes, which predicts early progression to castration-resistant prostate cancer (CRPC) and the development of aggressive variant...
|
- Details
- Zach Klaassen interviews Neal Shore about the EMBARK trial's post hoc analysis by age. The study examines the efficacy of enzalutamide alone or combined with leuprolide for high-risk biochemical recurrence in prostate cancer patients. Dr. Shore discusses the trial design, key results, and the implications of age stratification ( 70 years) on treatment outcomes and adverse events. The analysis show...
|
- Details
- Zach Klaassen interviews Joaquín Mateo about the ZZ-FIRST trial, which explores the combination of enzalutamide and talazoparib in metastatic hormone-naive prostate cancer. Dr. Mateo discusses the trial design, preliminary results, and the rationale behind combining AR-targeting agents with PARP inhibitors. The study shows promising results in terms of PSA complete response and early indications o...
|
- Details
- Fred Saad discusses the ARANOTE phase 3 study results, evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. The trial shows significant improvement in radiographic progression-free survival and secondary endpoints, including time to metastatic CRPC and pain progression. Dr. Saad emphasizes the favorable safety profile of darolutamide, with adverse events similar to pla...
|
- Details
- Cédric Pobel discusses an ancillary study of the PEACE-1 trial, focusing on phenotypic and genomic characterization of de novo metastatic prostate cancer. The study analyzes immunohistochemistry and genomic data from patient biopsies. Key findings include the identification of five phenotypes based on androgen receptor and neuroendocrine marker expression. Notably, about 25% of patients show neuro...
|
- Details
- Rashid Sayyid and Zachary Klaassen discuss the 2024 NCCN prostate cancer guideline updates for systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC). They highlight the new stratification of treatment recommendations based on disease volume and timing of metastases. The discussion covers recent clinical trials supporting triplet therapy for high-volume synchronous disease, inclu...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a meta-analysis published in JAMA Oncology examining cardiovascular events associated with androgen receptor signaling inhibitors (ARSIs) in advanced prostate cancer. The study analyzes 24 randomized controlled trials across various prostate cancer stages, involving 22,166 patients. Results show a significant increase in both all-grade and grade 3+ cardiovas...
|
- Details
- Giulia Marvaso discusses the RADIOSA trial, a phase II randomized study comparing SBRT alone versus SBRT with short-course hormonal therapy for oligorecurrent prostate cancer. The trial includes 102 patients with up to three metastatic lesions, randomized into two arms. Results show improved biochemical and clinical progression-free survival in the combination arm. Dr. Marvaso highlights that pati...
|
